Why the study?
Do protease-activated receptor-1 antagonists reduce ischemic events without increasing bleeding risk when added to standard antiplatelet therapy?
Do protease-activated receptor-1 antagonists reduce ischemic events without increasing bleeding risk when added to standard antiplatelet therapy?
Protease-activated receptor-1 antagonists like SCH 530348 represent a potential novel strategy to reduce ischemic events without increasing bleeding risk, with phase III trials ongoing.
Answers are grounded in this paper and cite their sources.
Phase II tolerability supports phase III evaluation of PAR-1 antagonists; leaves open any clinical role pending efficacy data.
Currently available antiplatelet agents have shown improved short- and long-term clinical outcomes but are associated with increased bleeding risk, and the rates of recurrent ischemic events still remain high. Selective inhibition of protease-activated receptor-1 for thrombin represents a potential novel strategy to reduce ischemic events without increasing the risk of bleeding. Two protease-activated receptor-1 antagonists are currently being evaluated in clinical trials: SCH 530348 and E5555. Results of phase II trials have shown that SCH 530348, when added to standard antiplatelet therapy, was well tolerated and not associated with increased bleeding risk. Two large-scale phase III trials assessing the efficacy of SCH 530348 in addition to the standard of care are currently ongoing. This review provides an outline of the current status of understanding on platelet thrombin-receptor antagonist SCH 530348, focusing on its pharmacologic properties and clinical development.
No takes yet. Share an insight, caveat, or question.
Sugunaraj et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: